| EPE0892 | Optimal use of PrEP to reduce HIV incidence by 90% by 2030 in a low incidence setting | E-poster | Costing, cost effectiveness and affordability |
| EPE0891 | Economic evaluation of HIV infection recency at four health facilities in Bangkok, Thailand | E-poster | Costing, cost effectiveness and affordability |
| EPE0890 | Analysis on the costing the adoption of Kenya’s HIV test and treat guidelines, and its implication on the economic growth | E-poster | Costing, cost effectiveness and affordability |
| EPE0889 | Cost-effectiveness of dolutegravir compared with efavirenz for prevention of perinatal transmission in women presenting with HIV in late pregnancy in Uganda | E-poster | Costing, cost effectiveness and affordability |
| EPE0888 | Cost-effectiveness of antiretroviral therapy adherence interventions in people living with HIV/AIDS: a systematic review of decision analytical models | E-poster | Costing, cost effectiveness and affordability |
| EPE0887 | Understanding the cost of pharmacy-delivered HIV pre- and post-exposure prophylaxis services in Kenya: findings from a pilot study | E-poster | Costing, cost effectiveness and affordability |
| EPE0886 | Cost-effectiveness of three different Pre-Exposure Prophylaxis (PrEP) regimens for HIV prevention in Mexico | E-poster | Costing, cost effectiveness and affordability |
| EPE0885 | Cost-effectiveness of treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV | E-poster | Costing, cost effectiveness and affordability |
| EPE0884 | Private sector financing to sustain health systems for orphans and vulnerable children (OVC) in Lagos State through the ICHSSA 2 project | E-poster | Global and national financing, economic evaluation and sustainability |
| EPE0883 | Aligning PEPFAR investments with health equity goals | E-poster | Global and national financing, economic evaluation and sustainability |